Monitor U.S. site activation and dosing in the randomized ARDS trial before year-end, and any FDA feedback on the adaptive Phase 2b/3 design. The company's cash runway ($7.5M) and operating burn rate suggest a need for additional financing within the next 2-3 quarters to fund the trial through its 2H2027 readout.
Drugs in focus
INKT drug pipeline →agenT-797
● Neutral Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $10.22entry
- T+1 · 5d ago −6.79%α −6.43% · $9.53
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
MiNK Therapeutics reported Q3 2026 net loss of $2.6M ($0.50 per share), narrower than the $2.9M loss ($0.65 per share) in the prior-year quarter, and recognized its first pre-commercial product revenue of $0.2M from named-patient access of agenT-797. The company ended the quarter with $7.5M in cash, down from $8.8M at June 30, 2026, and reported the lowest quarterly operating cash use of 2026 at $1.3M. Key catalysts include the ongoing randomized Phase 2 ARDS trial with U.S. dosing expected before year-end and data expected in 2H2027, and selection for ARPA-H's BoSS program (up to $87M in program-wide funding).
Key Financial Metrics
Key Facts
- Q3 2026 net loss $2.6M ($0.50 per share) vs $2.9M ($0.65) in prior-year quarter; 23% improvement in net loss per share
- First pre-commercial product revenue of $0.2M from named-patient access of agenT-797
- Cash and cash equivalents $7.5M at Sep 30, 2026, down from $8.8M at Jun 30, 2026
- Cash used in operations $1.3M in Q3 2026, lowest quarterly operating cash use of 2026
- General and administrative expense declined 44% to $1.0M
- Research and development expense increased to $1.8M from $1.1M, driven by randomized Phase 2 ARDS trial activity
- Randomized Phase 2 ARDS trial (C-1300-02) enrolling; U.S. dosing expected before year-end 2026; data expected 2H2027
- agenT-797 selected for ARPA-H BoSS program (Draper-led team; up to $87M program-wide funding)
- SITC 2026 data showed agenT-797 and MiNK-215 as 'living senolytics' in preclinical models
Financial Impact
Net loss improved 23% per share; first product revenue of $0.2M; cash burn reduced to $1.3M operating cash use in Q3
Risk Factors
- Cash runway limited; company may need to raise capital to fund randomized trial through readout
- Pre-commercial revenue is variable and depends on physician requests and regulatory authorizations
- Early clinical and preclinical data may not predict outcomes in controlled studies
- Randomized ARDS trial results are not expected until 2H2027, creating a long catalyst timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3400610 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Viewing Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers